What are Madrigal Pharmaceuticals, Inc.'s total assets?

Madrigal Pharmaceuticals, Inc. (MDGL) holds $1.2B in total assets, up 23.2% year over year.

How much debt does Madrigal Pharmaceuticals, Inc. have?

Madrigal Pharmaceuticals, Inc. carries $377.3M in total debt against $543.5M of shareholders' equity, a debt-to-equity ratio of 0.69.

How much cash does Madrigal Pharmaceuticals, Inc. have?

Madrigal Pharmaceuticals, Inc. holds $232.2M in cash and equivalents.

Can Madrigal Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 3.50 — current assets exceed current liabilities.

Where does Madrigal Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Madrigal Pharmaceuticals, Inc. MDGL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$203.78M+94.0%	$105.02M+5.1%	$99.92M-69.9%	$331.55M+814%
Short-term investments	$784.87M-5.0%	$826.23M+54.7%	$534.22M+1,862%	$27.23M-88.4%
Restricted cash	$5.09M+1.8%	$5M—	$0—	——
Accounts receivable, net	$388.42M+326%	$91.18M—	——	$0—
Inventories	$262.9M+418%	$50.71M—	$0—	$0—
Raw materials	$0—	$0—	$0—	——
Work in process	$67.63M+129%	$29.53M—	$0—	——
Finished goods	$7.21M+58.9%	$4.54M—	$0—	——
Prepaid expenses and other current assets	$47.8M+247%	$13.79M+338%	$3.15M+21.4%	$2.6M+93.9%
Total current assets	$1.25B+20.6%	$1.03B+62.1%	$637.28M+76.4%	$361.37M+33.0%
Property and equipment, net	$1.5M-31.6%	$2.19M+41.0%	$1.55M+158%	$601K-29.4%
Operating lease right-of-use assets	$4.94M+106%	$2.4M+40.2%	$1.71M+185%	$602K-24.5%
Intangible assets, net	$7.38M+56.1%	$4.73M—	$0—	——
Other non-current assets	$0—	——	——	——
Total assets	$1.26B+20.9%	$1.04B+62.7%	$640.55M+76.7%	$362.57M+32.6%
Accounts payable	$48.88M+12.1%	$43.6M+55.5%	$28.04M+17.7%	$23.83M+11.5%
Accrued expenses	$69.21M-44.5%	$124.7M+38.6%	$89.98M-1.6%	$91.46M+66.1%
Current portion of long-term debt	——	——	——	——
Operating lease liabilities, current	$1.02M+3.6%	$983K+86.5%	$527K-12.5%	$602K+46.8%
Accrued interest	——	——	——	——
Total current liabilities	$310.29M+83.3%	$169.28M+42.8%	$118.55M+2.3%	$115.89M+50.8%
Long-term debt	$339.88M+189%	$117.57M+1.8%	$115.48M+134%	$49.29M—
Operating lease liabilities, non-current	$6.73M+561%	$1.02M-14.2%	$1.19M—	$0-100%
Total noncurrent liabilities	$346.61M+192%	$118.59M+1.6%	$116.67M+137%	$49.29M+12,636%
Total liabilities	$656.9M+128%	$287.86M+22.4%	$235.21M+42.4%	$165.18M+114%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	200M+9,999,900%	2K0.0%	2K0.0%	2K0.0%
Additional paid-in capital	$2.69B+5.3%	$2.56B+46.8%	$1.74B+50.1%	$1.16B+34.3%
Retained earnings	-$2.09B-16.0%	-$1.8B-34.9%	-$1.34B-38.8%	-$962.66M-44.3%
Accumulated other comprehensive income (loss)	$873K+86.5%	$468K0.0%	$468K+1,563%	-$32K+60.0%
Total stockholders' equity	$602.69M-20.1%	$754.38M+86.1%	$405.33M+105%	$197.39M+0.7%
Total liabilities and stockholders' equity	$1.26B+20.9%	$1.04B+62.7%	$640.55M+76.7%	$362.57M+32.6%
Allowance for Doubtful Accounts	$0—	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	$0—	——	——	——
Available For Sale Securities Debt Securities Current	$784.87M-5.0%	$826.23M+54.7%	$534.22M+1,862%	$27.23M-88.4%
Finished goods	$7.21M+58.9%	$4.54M—	$0—	——
Deferred Tax Assets and Other Non-Current Assets	$0—	——	——	——
Net Investment in Lease	$4.94M+106%	$2.4M+40.2%	$1.71M+185%	$602K-24.5%
Intangible assets — net	$7.38M+56.1%	$4.73M—	$0—	——
Operating lease right-of-use assets	$4.94M+106%	$2.4M+40.2%	$1.71M+185%	$602K-24.5%
Other non-current assets	$0—	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$4.94M+106%	$2.4M+40.2%	$1.71M+185%	$602K-24.5%
Software and Technology Licenses, Net	$0—	——	——	——
Accrued Manufacturing Costs	$69.21M+98.0%	$34.96M+105%	$17.03M—	——
Other Commercial Liabilities	$260.39M+109%	$124.7M+38.6%	$89.98M-1.6%	$91.46M+66.1%
Accrued Liabilities, Current	$260.39M+109%	$124.7M+38.6%	$89.98M-1.6%	$91.46M+66.1%
Compensation and benefits	$69.21M+98.0%	$34.96M+105%	$17.03M—	——
Debt Maturity - 2024	——	——	——	——
Debt Maturity - 2027	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	——	——	——	——
Total debt	$347.63M+191%	$119.57M+2.0%	$117.19M+135%	$49.89M+6,160%
Total Carrying Value of Debt	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	22.8M+3.8%	22M+10.7%	19.9M+9.8%	18.1M+5.8%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	2.4M0.0%	2.4M0.0%	2.4M0.0%	2.4M+20.3%
Convertible Preferred Stock Outstanding Shares	2.4M0.0%	2.4M0.0%	2.4M0.0%	2.4M+20.3%
Additional paid-in capital	$2.69B+5.3%	$2.56B+46.8%	$1.74B+50.1%	$1.16B+34.3%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Number of Exercisable Options	——	——	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	979.9K-35.9%	1.5M-35.1%	2.4M—	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Unrealized Gains on Investments	$879K+40.6%	$625K+31.3%	$476K—	——
Unrealized Losses on Investments (Before Tax)	$20K-87.3%	$157K+1,863%	$8K—	——
Weighted Average Exercise Price of Outstanding Options	$155.25+65.9%	$93.57+17.1%	$79.94—	——
Clinical study, manufacturing and drug supply	$26.91M—	——	——	——
Selling, general and administrative	$40.03M—	——	——	——
Accounts Receivable, Allowance for Credit Loss	$0—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$20K-87.3%	$157K+1,863%	$8K—	——
Gross Unrealized Gains	$879K+40.6%	$625K+31.3%	$476K—	——
Cash, Cash Equivalents, Restricted Cash and Short-term Investments, At Cost	$987.79M—	——	——	——
Fair value	$988.65M—	——	——	——
Stock options, restricted stock and performance stock units convertible, shares issuable (in shares)	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$200M0.0%	$200M0.0%	$200M0.0%	$200M0.0%
Common stock, shares issued (in shares)	$22.84M+3.8%	$22M+10.7%	$19.88M+9.8%	$18.1M+5.8%
Common Stock, Shares, Outstanding	$22.84M+3.8%	$22M+10.7%	$19.88M+9.8%	$18.1M+5.8%
Long-term debt, gross	——	——	——	——
Less: net unamortized discount	——	——	——	——
Unrecognized compensation cost related to non-vested awards	——	——	——	——
Gross To Net Adjustments Reserve	$99.34M+284%	$25.89M—	——	——
2028	——	——	——	——
2029	——	——	——	——
2030	——	——	——	——
2027	——	——	——	——
Remainder of 2026	——	——	——	——
Number of office lease amendment	——	——	——	——
Other accrued liabilities	$33.74M+313%	$8.17M+315%	$1.97M+157%	$767K-78.2%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$2.37M0.0%	$2.37M0.0%	$2.37M0.0%	$2.37M+20.3%
Preferred Stock, Shares Outstanding	$2.37M0.0%	$2.37M0.0%	$2.37M0.0%	$2.37M+20.3%
Provision for excess inventory	$0—	$0—	——	——
Purchase Obligation	——	——	——	——
Rebates, returns and other revenue related reserves	$90.5M—	——	——	——
Number of research and development categories	——	——	——	——
Number of selling, general and administrative categories	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$979.86K-35.9%	$1.53M-35.1%	$2.36M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$155.25+65.9%	$93.57+17.1%	$79.94—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——
Purchase Obligation	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Madrigal Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Madrigal Pharmaceuticals, Inc.'s total assets?: Madrigal Pharmaceuticals, Inc. (MDGL) holds $1.2B in total assets, up 23.2% year over year.
How much debt does Madrigal Pharmaceuticals, Inc. have?: Madrigal Pharmaceuticals, Inc. carries $377.3M in total debt against $543.5M of shareholders' equity, a debt-to-equity ratio of 0.69.
How much cash does Madrigal Pharmaceuticals, Inc. have?: Madrigal Pharmaceuticals, Inc. holds $232.2M in cash and equivalents.
Can Madrigal Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 3.50 — current assets exceed current liabilities.
Where does Madrigal Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from Madrigal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.